



FOR IMMEDIATE RELEASE

Veeva CDB Application to Streamline Aggregation, Cleaning, and Transformation of Clinical Data

New clinical data application harmonizes study data from multiple sources to provide complete and concurrent clinical trial data

BARCELONA, Spain — 18 Oct. 2022 — Veeva Systems (NYSE: VEEV) announced the availability of Veeva CDB, a first-of-its-kind solution for aggregating, cleaning, and transforming clinical data. Veeva CDB will evolve the way clinical data management teams work by providing a platform for ingestion and review of all study data sources while reducing the manual processes, integration projects, complexity, and costs associated with making clinical trial data usable.

With Veeva CDB, sponsors and data providers can view and resolve data queries centrally to minimize quality risks, provide better data visibility, and speed trial execution. Veeva CDB's automated ingestion engine brings together data from a wide range of external sources, including EDC, RTSM, ePRO, eCOA, and lab data. Ingestion from Veeva Vault EDC is available today, and support for other third-party EDC systems, including Medidata Rave™, is planned for 2023.

"With the increase of digital data sources in clinical trials, effective data management has become a key driver of study success," said Mayank Anand, vice president and global head of data strategy and management at GSK. "Veeva CDB speeds aggregation and cleaning, allowing our data managers to focus on value-added activities that can move our trials forward."

"We have worked closely with 10 clinical trial sponsors and CROs and 18 of their key data providers to develop and refine Veeva CDB over the past two years," said Pavel Burmenko, general manager, Veeva CDB. "In more than 100 trials to date, Veeva CDB has delivered analysis-ready data faster for more informed decisions and streamlined execution across all trial partners."

The Veeva CDB Data Provider Program also announced today will — for the first time ever — bring sponsors, CROs, and data providers together on a single clinical data management platform to facilitate the delivery of quality data faster and more efficiently. The program enables qualified data providers with tools, training, and support to supply data using a standardized and streamlined method for Veeva CDB customers.

"In line with our commitment to enable evidence generation in modern clinical trials, we are pleased to partner with Veeva to support our mutual customers' data integration needs," said Ian Jennings, chief commercial officer at Signant Health.

Learn how Veeva CDB transforms the role of the data manager and delivers faster insights at [Veeva R&D and Quality Summit](#). Life sciences industry professionals can [register](#) for the Oct. 19 and 20 in-person event in Boston.

Additional Information

For more on Veeva CDB, visit: veeva.com/eu/CDB

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

Follow @veeva_eu on Twitter: twitter.com/veeva_eu

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Veeva Forward-looking Statements

This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services, including certain of our new solutions and applications that are still under development or not generally available. These statements are based on our current expectations. Actual results, availability, and any future events relating to these products and services could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2022, which you can find [here](#) (a summary of risks which may impact our business can be found on pages 39 and 40), and in our subsequent SEC filings, which you can access at [sec.gov](https://www.sec.gov).

###

Contact:

Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com

Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com